statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Expands By 91.7%

Avenue Therapeutics, Inc. (NASDAQ:ATXI - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 313,400...

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...

Avenue Therapeutics granted extension for Nasdaq compliance

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg ( GAERS ) model of absence epilepsy-MIAMI, Feb...

Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Growth in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI  Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest...

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization of...

Why Avenue Therapeutics Shares Are Getting Hammered

Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 31% to $0.24 Friday morning after the company announced it has entered into warrant exercise agreements with existing read more...

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

Volume	133,754.00
52-Wk High	$82.50
52-Wk Low	$2.60

ATXI Avenue Therapeutics Inc

About

Feed

News

Fundamentals